Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01.05.2023 - Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 ...
These names had short positions amounting to at least 25% of their total float at the end of March, according to FactSet.
Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating)’s stock price was down 5.7% during trading on Monday . The company traded as low as $22.51 and last traded at $22.61. Approximately 443,067 shares were traded during trading, a decline of 63% from the average daily volume of 1,193,483 shares. The stock had previously closed at $23.97. […]
Shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) traded down 4.7% during trading on Wednesday . The stock traded as low as $24.45 and last traded at $24.50. 598,717 shares changed hands during trading, a decline of 55% from the average session volume of 1,318,895 shares. The stock had previously closed at $25.71. Wall […]
The S&P 500 on Monday seems a little more optimistic after last week's travails. The S&P 500 opened up 0.4% before the open, while the Dow advanced 1